← Back to Search

Vasoconstrictor

Vasopressin for Fontan Physiology

Q: To what extent is patient participation in this experiment increasing?

<p>Affirmative. The details posted on clinicaltrials.gov suggest that this research is currently attempting to enlist participants; the trial was initially reported in August of 2020, with its most recent update being February 13th 2022. Approximately 50 patients must be sourced from 2 distinct facilities.</p>

Q: Are there opportunities for new participants to join this scientific experiment?

<p>Affirmative. The information on clinicaltrials.gov shows that this study is actively seeking volunteers, which was initially published on August 12th 2020 and last edited February 13th 2022. This trial requires 50 individuals to be enrolled at two medical sites.</p>

Phase < 1

Waitlist Available

Led By Manchula Navaratnam, MD

Research Sponsored by Stanford University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Timeline

Screening 3 weeks

Treatment Varies

Follow Up pre-dose, every 5 minutes post-dose for approximately 15 minutes (post-baseline values will be averaged)

Awards & highlights

Study Summary

This trial will study the effects of vasopressin on blood pressure in people with Fontan physiology.

Eligible Conditions

Fontan Physiology
Low Blood Pressure

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ pre-dose, every 5 minutes post-dose for approximately 15 minutes (post-baseline values will be averaged)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~pre-dose, every 5 minutes post-dose for approximately 15 minutes (post-baseline values will be averaged)

This trial's timeline: 3 weeks for screening, Varies for treatment, and pre-dose, every 5 minutes post-dose for approximately 15 minutes (post-baseline values will be averaged) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in pulmonary artery pressure

Change in systemic (aortic) blood pressure

Change in transpulmonary gradient

+1 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: VasopressinExperimental Treatment1 Intervention

Participants undergoing cardiac catheterization

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Vasopressin

2014

Completed Phase 4

~24780

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Stanford UniversityLead Sponsor

2,395 Previous Clinical Trials

17,341,327 Total Patients Enrolled

1 Trials studying Fontan Physiology

12 Patients Enrolled for Fontan Physiology

Manchula Navaratnam, MDPrincipal Investigator - Stanford University

Stanford University

1 Previous Clinical Trials

12 Total Patients Enrolled

1 Trials studying Fontan Physiology

12 Patients Enrolled for Fontan Physiology

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

To what extent is patient participation in this experiment increasing?

"Affirmative. The details posted on clinicaltrials.gov suggest that this research is currently attempting to enlist participants; the trial was initially reported in August of 2020, with its most recent update being February 13th 2022. Approximately 50 patients must be sourced from 2 distinct facilities."

Answered by AI

Are there opportunities for new participants to join this scientific experiment?

"Affirmative. The information on clinicaltrials.gov shows that this study is actively seeking volunteers, which was initially published on August 12th 2020 and last edited February 13th 2022. This trial requires 50 individuals to be enrolled at two medical sites."

Answered by AI

Recent research and studies

World Journal for Pediatric and Congenital Heart SurgeryJournal

Vasopressin After the Fontan Operation

Kumar, T. K. Susheel, Pooja Kashyap, Mayte Figueroa, David Zurakowski, Jerry Allen, Jean A. Ballweg, Shyam Sathanandam, Mohammed Ali MD, and Christopher J. Knott-Craig. 2015. “Vasopressin After the Fontan Operation”. World Journal for Pediatric and Congenital Heart Surgery. SAGE Publications. doi:10.1177/2150135115614574.

The Annals of Thoracic SurgeryJournal

Safety and Efficacy of Vasopressin After Fontan Completion: A Randomized Pilot Study

Bigelow, Amee M., Nancy S. Ghanayem, Nathan E. Thompson, John P. Scott, Laura D. Cassidy, Katherine J. Woods, Ronald K. Woods, Michael E. Mitchell, Viktor Hraŝka, and George M. Hoffman. 2019. “Safety and Efficacy of Vasopressin After Fontan Completion: A Randomized Pilot Study”. The Annals of Thoracic Surgery. Elsevier BV. doi:10.1016/j.athoracsur.2019.06.053.

Pediatric Critical Care MedicineJournal

Hemodynamic Effects of Phenylephrine, Vasopressin, and Epinephrine in Children with Pulmonary Hypertension

Siehr, Stephanie L., Jeffrey A. Feinstein, Weiguang Yang, Lynn F. Peng, Michelle T. Ogawa, and Chandra Ramamoorthy. 2016. “Hemodynamic Effects of Phenylephrine, Vasopressin, and Epinephrine in Children with Pulmonary Hypertension”. Pediatric Critical Care Medicine. Ovid Technologies (Wolters Kluwer Health). doi:10.1097/pcc.0000000000000716.

clinicaltrials.govStudy